CRWEFinance.com Hot Stock News & Alerts!
________________________________________
FREE Daily Stock Alerts From CRWEFinance.com
________________________________________
CRWEFinance.com Stock Report!
Be sure to check out more news at crwefinance.ning.com as well.
********************************************************************************
HOUSTON, Jan. 20, 2010 (CRWENEWSWIRE) — Power3 Medical Products, Inc. (OTCBB:PWRM - News) is pleased to announce that the company will be a sponsor and have an exhibit booth at the 4th Annual Conference of the Alzheimer’s Drug Discovery Foundation on Drug Discovery for Neurodegeneration in Houston on February 1-2, 2010.
“This meeting is particularly appropriate for the company. The NuroPro® blood protein biomarkers and tests for early detection, differential diagnosis, and monitoring of therapeutic response of Alzheimer’s disease, Parkinson’s disease and ALS are progressing through clinical validation trials,” said Dr. Ira L. Goldknopf, Chief Scientific Officer. “Power3 remains at the forefront of this area.”
“I am proud of the continued progress of Power3 in the neurodegenerative diseases. We are continuing publication and promotion of the exciting results of our clinical validation trials in these areas and are glad to have the opportunity to move into the marketing area of drug discovery,” said Helen R. Park, CEO of Power3 Medical. “We are eager to make an impact in drug discovery for neurodegenerative disease and think our presence at this conference will provide inroads into that area.”
About Power3 Medical Products, Inc.
Power3 Medical Products, http://www.Power3Medical.com, is a leader in bio-medical research and the commercialization of neurodegenerative disease and cancer biomarkers, pathways, and mechanisms of diseases through the development of diagnostic tests and drug targets. Power3’s patent-pending technologies are being used to develop screening and diagnostic tests for the early detection and prognosis of disease, identify protein biomarkers, and drug targets, and its diagnostic tests are targeted toward markets with critical unmet needs in areas including neurodegenerative disease (NuroPro) and breast cancer (BC-SeraPro). Power3 operates a state-of-the-art CLIA certified laboratory in The Woodlands (Houston), Texas and continues to evolve and enhance its IP portfolio, employing sensitive and specific combinations of biomarkers it has discovered from a broad range of diseases as the basis of highly selective blood-based tests for ALS, Alzheimer’s, and Parkinson’s diseases, breast cancer, and drug resistance.
For more information visit, http://www.Power3Medical.com
Forward-Looking Statement:
This release may contain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements and/or Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995 are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. Risks and uncertainties applicable to the company and its business could cause the company’s actual results to differ materially from those indicated in any forward-looking statements.
Contact:
Crown Equity Holdings, Inc.
877 854-6797
702 448-1543
***********Advertisement***********
.png)
.png)
.png)
Disclaimer: Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. CRWEFinance.com publisher and its affiliates and contractors are not registered investment advisers or broker/dealers. Our disclaimer is to be read and fully understood before using our site, reading our newsletter or joining our email list. Release of Liability: Through use of this website viewing or using, you agree to hold CRWEFinance.com report and Crown Equity Holdings, Inc. CRWE, its operators, shareholders, employees and/or contractors harmless and to completely release them from any and all liability due to any and all loss (monetary or otherwise), damages (monetary or otherwise) that you may occur. (read more ) Rule 17B requires disclosure of payment for investor relations. Crown Equity Holdings, Inc. (CRWE.OB) has previously received five hundred thousand shares compensation for 30 days of advertisement services and has received an additional 1,000,000 shares 144 restricted stocks for 6 months of advertisement and diseminate news and $15,000 dollars for IR services for Power 3 Medical Products Inc. (PWRM.OB).
